Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited].

PMID: 41293705 · 2025

JournalBiomedical optics express
Year2025
PMID41293705

Abstract

Photoacoustic imaging (PAI) combines optical contrast with acoustic detection to enable high-resolution, molecular imaging at clinically relevant depths. This review outlines the current status and future potential of contrast-enhanced PAI in human applications. We begin by discussing regulatory considerations surrounding both imaging devices and exogenous contrast agents, highlighting safety concerns, lack of standardized validation protocols, and barriers to the approval of novel agents. To ac

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.